London, October 31st 2014 – ReViral Ltd is pleased to announce the appointment of Max Herrmann (48) as the company’s Chief Financial Officer with effect from October 31st, 2014.
Max possesses more than 20 years of biotechnology and pharmaceutical industry experience having held key management positions with leading development stage companies, as well as several investment banks. In his industry and investment banking roles, Max has been involved in the raising of more than $400M for biotechnology companies in the United States and Europe. He is also currently a Partner at Oriel Securities Limited and prior to this was was Chief Financial Officer of Silence Therapeutics plc. In addition, Max has also spent over 10 years as a sell-side equity analyst most latterly as Managing Director and Head of European Pharmaceutical and Biotechnology Research at ING. Prior to his successful career in the City, Max worked in the US for Onyx Pharmaceuticals Inc. as financial controller, where he was involved in the company’s successful IPO on NASDAQ.
Max qualified as a Chartered Accountant with Arthur Andersen in 1993. He holds a degree in Microbiology from the University of Kent.
“We are very pleased that an individual of Max’s calibre has joined the reViral team and are confident that his range of financial and operational experience will greatly add to the long-term success of the company,” stated Khatereh Ahmadi, Chief Executive Officer of reViral. “I am confident Max’s experience and expertise will serve the company well as we continue to develop reViral’s novel RSV antivirals.”
Max Herrmann commented: “there is a growing understanding of the commercial potential of antiviral to treat RSV infections. I am looking forward to joining one of the leading players in this field”.